Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations
Dove Medical Press Therapeutic advances are needed in PV as phlebotomy, low-dose aspirin, cytoreductive agents, and interferon alpha are the only therapeutic tools available at the moment to influence outcome. Even though several questions are still unanswered, this ... |
from phlebotomy - Google News http://bit.ly/2dc5iai
No comments:
Post a Comment